BRIEF published on 09/30/2024 at 09:06, 1 year 2 months ago VOQUZ Labs AG: H1 '24 Performance and Future Prospects VOQUZ Labs AG EBITDA Growth H1 '24 Report VisoryQ S4/HANA Transformation
PRESS RELEASE published on 09/30/2024 at 09:01, 1 year 2 months ago Original-Research: VOQUZ Labs AG (von NuWays AG): BUY VOQUZ Labs AG releases final H1 '24 report, with sales up by 25% yoy and EBITDA at €0.3m. Confirms FY guidance of 10-20% top-line growth and 15-20% EBITDA margin EBITDA Sales Growth VOQUZ Labs AG FY Guidance H1 Report
BRIEF published on 08/15/2024 at 09:06, 1 year 3 months ago VOQUZ Labs AG Delivers Strong Preliminary H1 Results and Reaffirms BUY Rating EBITDA Margin Sales Growth NuWays AG H1 Results VOQUZ Labs
PRESS RELEASE published on 08/15/2024 at 09:01, 1 year 3 months ago Original-Research: VOQUZ Labs AG (von NuWays AG): BUY VOQUZ Labs AG shows strong H1 results with 24.9% sales growth and increased EBITDA margin. Partnership with PwC Germany and new product launch expected to drive future growth EBITDA Margin Sales Growth VOQUZ Labs AG H1 Results PwC Germany
BRIEF published on 04/10/2024 at 09:07, 1 year 7 months ago VOQUZ Labs AG Foresees Strong Growth and Continues M&A Strategy VOQUZ Labs AG Financial Analysis Stock Market Mergers & Acquisitions S/4HANA Transformation
PRESS RELEASE published on 04/10/2024 at 09:02, 1 year 7 months ago Original-Research: VOQUZ Labs AG (von NuWays AG): Kaufen Update on VOQUZ Labs AG after the acquisition of NuWays AG, showcasing strong momentum with growth in key solutions and M&A strategy. Analyst recommends 'Kaufen' (Buy) with a target price of EUR 22.00 Acquisition VOQUZ Labs AG NuWays AG Growth Analyst Recommendation
BRIEF published on 03/22/2024 at 09:07, 1 year 8 months ago VOQUZ Labs AG Partners with PwC to Accelerate Market Penetration of remQ Software VOQUZ Labs AG SAP PwC Partnership RemQ Software ERP Transition
PRESS RELEASE published on 03/22/2024 at 09:02, 1 year 8 months ago Original-Research: VOQUZ Labs AG (von NuWays AG): Kaufen VOQUZ Labs AG announces strategic partnership with PwC Solutions Germany to market remQ software for SAP customers. Analyst: Philipp Sennewald recommends buying with a target price of EUR 22.00. Potential growth expected VOQUZ Labs AG PwC Partnership RemQ Software SAP Customers Financial Incentives
BRIEF published on 03/07/2024 at 09:06, 1 year 8 months ago VOQUZ Labs AG Receives "BUY" Rating with Promising Yearly Outlook from NuWays AG VOQUZ Labs AG NuWays AG Financial Analysis Market Outlook Stock Recommendation
PRESS RELEASE published on 03/07/2024 at 09:01, 1 year 8 months ago Original-Research: VOQUZ Labs AG (von NuWays AG): BUY VOQUZ Labs AG announces strong results for FY '23 with promising outlook for FY '24. H2 sales up 16% yoy, EBITDA positive at €0.4m. Target price increased to €22. Recommendation: BUY Buy Recommendation VOQUZ Labs AG FY '23 Results FY '24 Outlook Strong Sales Growth
Published on 12/05/2025 at 02:35, 3 hours 30 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 5 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 5 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 35 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 14 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 40 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 50 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 55 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 5 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 20 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 21 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 4 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
